Table 3.

Comparison of patients using β-blockers versus patients using other BPLMs only from the CPRD and DIN studies: pooled HRs (95% CI) from meta-analyses of cancer site-specific results

Comparison (vs controls)	CPRD	DIN	p Value†
All patients using β-blockers	1.01 (0.91 to 1.13)	1.18 (1.04 to 1.33)**	0.06
Patients using β-blockers only	0.94 (0.82 to 1.07)	1.37 (1.16 to 1.61)***	<0.001***
β-Blockers and other BPLM	1.06 (0.95 to 1.19)	1.11 (0.91 to 1.34)	0.69
Non-selective β-blockers only	0.96 (0.8 to 1.15)	1.21 (0.94 to 1.55)	0.14

**p<0.01; ***p<0.001.

†Wald tests of CPRD vs DIN HRs.

BPLMs, blood pressure lowering medicines; CPRD, Clinical Practice Research Datalink; DIN, Doctors’ Independent Network.